Physician profile
Divya Sachdev
NPI 1316204936
$2,192.91
in general payments reported to CMS, 2019-2025
19 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.54 · 2022: $12.69 · 2023: $382 · 2024: $479 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.94 | 2023-2025 | Skyrizi |
| Janssen Biotech, INC. | $235.50 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $193.96 | 2023-2025 | |
| Revance Therapeutics, INC. | $191.88 | 2024-2025 | Daxxify, Daxi |
| Genzyme Corporation | $167.64 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $163.48 | 2024-2025 | Zoryve |
| Ucb, INC. | $156.00 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $98.57 | 2024-2025 | Adbry, Anzupgo |
| Amgen INC. | $73.76 | 2023-2024 | Otezla |
| Incyte Corporation | $56.28 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $55.51 | 2023 | Sotyktu |
| Almirall LLC | $44.52 | 2025 | Seysara, Klisyri |
| Merz North America, INC. | $42.76 | 2023-2024 | Xeomin |
| Galderma Laboratories, L.P. | $35.43 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.62 | 2025 | Spevigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.35 | 2025 | Taltz, Ebglyss |
| Celgene Corporation | $16.54 | 2019 | |
| Botanix Sb INC | $15.48 | 2025 | Sofdra |
| Medimetriks Pharmaceuticals, INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.